Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | GBA1 | P04062 | 1/20 | 0.36 |
| ▸ | UGCG | Q16739 | 1/20 | 0.36 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.32 |
| ▸ | KMO | O15229 | 2/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.32 |
| ▸ | SCD | O00767 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | PDE2A | O00408 | 2/20 | 0.30 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.30 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.30 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.30 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2411021 | 1.00 | DYRK1A (0.38) | DYRK1AGBA1UGCGGBA2ADORA2B | |
| SCHEMBL2410535 | 0.88 | CYP11B2 (0.39) | DYRK1AGBA1UGCGGBA2KMO | |
| SCHEMBL2410541 | 0.88 | CYP11B2 (0.39) | DYRK1AGBA1UGCGGBA2KMO | |
| SCHEMBL2410548 | 0.87 | DYRK1A (0.41) | DYRK1AKMOAAK1 | |
| SCHEMBL2410556 | 0.87 | DYRK1A (0.41) | DYRK1AKMOAAK1 | |
| SCHEMBL2413268 | 0.86 | DYRK1A (0.36) | DYRK1AKMOADORA3 | |
| SCHEMBL2413272 | 0.86 | DYRK1A (0.36) | DYRK1AKMOADORA3 | |
| SCHEMBL315119 | 0.85 | GBA1 (0.34) | GBA1UGCGGBA2AAK1 | |
| SCHEMBL315120 | 0.85 | GBA1 (0.34) | GBA1UGCGGBA2AAK1 | |
| SCHEMBL2418141 | 0.84 | GBA1 (0.36) | GBA1UGCGGBA2AAK1PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8013010-B2 | 5-thioxylopyranose compounds | LABORATOIRES FOURNIER S.A. (FR) | 2011-09-06 | — | — | US | disclosed |
| US-20090186840-A1 | 5-Thioxylopyranose Compounds | LABORATOIRES FOURNIER S.A (FR) | 2009-07-23 | — | — | US | disclosed |
| EP-2066681-A1 | NEW DERIVATIVES OF 5-THIOXILOPYRANOSE | LABORATOIRES FOURNIER SA (FR) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008037923-A1 | NEW DERIVATIVES OF 5-THIOXILOPYRANOSE | LABORATOIRES FOURNIER S.A. (FR) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186840-A1 | 5-Thioxylopyranose Compounds | TPMT, PNPO, CYP3A5 | DYRK1A 4436/4885GBA1 3030/4885UGCG 1119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.